Subscribe X
Back to Top

Learn

October 9, 2018 by Peter Simons | MadInAmerica.com

Two-Thirds of Schizophrenia Patients Do Not Remit on Antipsychotics

A new analysis of antipsychotic treatment of schizophrenia has found that two-thirds of patients do not experience symptom remission.

A new analysis of antipsychotic treatment of schizophrenia (published in Schizophrenia Bulletin) has found that two-thirds of patients treated this way do not experience symptom remission. Additionally, one in five did not experience any improvement at all. The research was led by Myrto Samara, Adriani Nikolakopoulou, Georgia Salanti, and Stefan Leucht, working through the Institute of Social and Preventive Medicine (ISPM) at the University of Bern, Switzerland.

The authors note that treatment guidelines, textbooks, and other resources on psychiatry generally make vague statements that somewhere between 10% and 60% of patients do not benefit from antipsychotic medications or experience only a “partial” improvement. These resources also generally fail to cite references for their numbers.

Samara and the other researchers write that “The treatment guidelines from the American Psychiatric Association mention that ‘about 10%–30% of patients have little or no response to antipsychotic medications, and up to an additional 30% of patients have partial responses to treatment,’ but the authors fail to provide any reference.” However, that does equate to about 60% of patients who do not sufficiently improve when taking antipsychotics, which matches the new data.

The researchers analyzed the data from 16 randomized controlled trials (RCTs), considered the gold standard of evidence for clinical studies. This included 6,221 participants with a diagnosis of schizophrenia who were assigned to take one antipsychotic medication from the following list: amisulpride, flupenthixol, haloperidol, olanzapine, quetiapine, risperidone, or ziprasidone. Their progress was assessed over 4-6 weeks, depending on the study.

Samara and colleagues reported finding that “The overall percentage of no symptomatic remission was 66.9%”—meaning that only about a third of people with schizophrenia experienced full improvement on antipsychotic medications. 19.8% of the patients in the study did not experience any improvement at all after taking antipsychotic drugs.

The researchers also report data using numerous cut-off points, because different definitions of “symptom remission” and “improvement” exist in the clinical literature. Notably, if a more stringent definition was used (requiring at least a 75% reduction in symptom severity), only about 13% of participants improved.

According to Samara and the other researchers, those who were diagnosed with schizophrenia at a younger age and those whose symptoms were less severe were less likely to improve. Additionally, certain antipsychotics appeared to have higher rates of response. However, the researchers caution that because their study was not designed to test which antipsychotics were more efficacious, these results cannot be interpreted.


Samara, M. T.,  Nikolakopoulou, A., Salanti, G., & Leucht, S. (2018). How many patients with schizophrenia do not respond to antipsychotic drugs in the short term? An analysis based on individual patient data from randomized controlled trialsSchizophrenia Bulletin. doi:10.1093/schbul/sby095

Source: MadInAmerica.com/2018/10/two-thirds-antipsychotic-users-not-benefit-schizophrenia/

One thought on “Two-Thirds of Schizophrenia Patients Do Not Remit on Antipsychotics

  1. Ben Cooley Hall says:

    It’s tempting to see this study as vindication for those of us who question pharmaceutical use and instead favor deprescribing. However, most antipsychotic studies that support the alternative hypothesis–i.e., that the medication is effective–only measure short-term effects while failing to measure long-term effects, which are often far worse. If this study seeks to debunk the myth of short-term efficaciousness, readers should also keep in mind that this is only part of the issue. The equally pervasive myth of long-term efficaciousness (“S/he just didn’t have a long enough trial/an adequate dose/sufficient compliance” etc.) must also be roundly debunked. I suppose every brick helps, though, so thanks to the authors of this study and of this review.

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.


Related Blogs

  • Dr. David Healy

    Dr. David Healy

    Dr. Healy is a professor of psychiatry at Cardiff University in Wales and an author on the history of pharmaceuticals and government regulation.
    READ BLOG
  • Mad In America: Robert Whitaker

    Mad In America: Robert Whitaker

    Journalist and author Bob Whitaker distills the latest in pharmaceutical and mental health research.
    READ BLOG
  • Selling Sickness

    Selling Sickness

    Creating a new partnership movement to challenge the selling of sickness.
    READ BLOG
  • Kathy Brous

    Kathy Brous

    A serial of Kathy's recovery journey as an adult with attachment disorder.
    READ BLOG
  • Nev Jones

    Nev Jones

    Exploring the intersections of psychiatry, philosophy, neuroscience, cultural theory, critical community psychology and the mad/user/survivor movement.
    READ BLOG
  • 1boringoldman

    1boringoldman

    Retired psychiatrist and raconteur offers insightful analysis of the day's events from the woods of Georgia.
    READ BLOG